Sarcoma Awareness Month 2026: Research and Clinical Trials

What sarcoma is

Sarcoma is a cancer that starts in the body’s connective tissues. Connective tissue is the material that holds the rest of the body together. It includes bone, muscle, fat, cartilage, blood vessels, nerves, and the tissue around joints. When a cancer begins in any of these tissues, doctors group it under the umbrella term sarcoma. This is different from carcinoma, the more common cancer category that starts in the cells lining organs and skin.

Sarcoma divides broadly into two groups. Soft tissue sarcoma begins in muscle, fat, blood vessels, nerves, tendons, or the tissue around joints. Bone sarcoma, sometimes called primary bone cancer, begins in the bone itself. The two groups are clinically distinct and require different diagnostic and treatment approaches, but they share enough biological and structural features to be considered together under one umbrella term.

According to the American Cancer Society, an estimated 13,910 new cases of soft tissue sarcoma and 4,110 new cases of bone and joint sarcoma are projected in the United States in 2026. Together that is roughly 18,000 sarcoma diagnoses in a country where more than 2 million cancers are diagnosed each year. Sarcoma represents less than 1% of adult cancer diagnoses, but it represents close to 15% of cancers diagnosed in children and adolescents.

Sarcoma and Bone Cancer Awareness Month is observed throughout July across the United States and in many other countries. The observance focuses public attention on a cancer group that most people have never heard of and that primary care clinicians may see only a handful of times across their careers. Much of the progress against sarcoma over the past two decades has come from clinical research, where small, targeted studies have gradually built the evidence base that now guides specialist care.

Why sarcoma is called the forgotten cancer

Sarcoma is often called the forgotten cancer. The label captures three features of the disease that distinguish it from cancers that draw more public attention.

The first feature is rarity. Sarcoma accounts for less than 1% of adult cancers in the United States. Public health campaigns, research funding, and pharmaceutical investment tend to follow large patient populations, so cancers with bigger absolute numbers attract more visibility and infrastructure. Sarcoma sits at the opposite end of that distribution.

The second feature is heterogeneity. Sarcoma is not a single disease. Pathologists and oncologists recognize more than 70 distinct subtypes, each defined by the tissue of origin, the cellular pattern under the microscope, and increasingly the underlying genetic changes that drive tumor growth. Some subtypes are so uncommon that fewer than one in a million people are diagnosed with them in a given year. The category called ultra-rare sarcomas accounts for roughly 20% of all sarcoma diagnoses, which means a meaningful share of sarcoma patients have a subtype that almost no clinician outside a specialist center has encountered before.

The third feature is who it affects. More than half of all sarcomas occur in adolescents and young adults aged 15 to 39, and bone sarcomas in particular cluster in the second and third decades of life. Osteosarcoma, the most common form of bone cancer, is most often diagnosed in teenagers and young adults during periods of rapid bone growth. This age distribution is uncommon among cancers, most of which become more frequent with age.

The combined effect is a cancer group that is hard to recognize, hard to study at scale, and hard to fund, but that takes a disproportionate toll on younger people in the United States. Clinical research in rare diseases has become one of the main avenues through which the field is beginning to close that gap.

Signs to know and the diagnostic path

The earliest sign of soft tissue sarcoma is often a painless lump or area of swelling that grows over weeks or months. The lump may sit deep in the thigh, the upper arm, the chest wall, or the abdomen, and it commonly does not cause symptoms until it begins to press on nearby structures. Painless lumps are usually benign in everyday clinical practice, since fatty cysts, lipomas, ganglion cysts, and similar non-cancerous growths are far more common than sarcoma. That background of low base-rate suspicion is part of why sarcoma diagnoses are often delayed.

Bone sarcoma presents differently. The most common early symptoms are persistent bone pain that does not follow an obvious injury, pain that wakes a person from sleep, swelling or a visible lump over the bone, and in some cases a fracture from minor trauma. In adolescents and young adults, persistent bone pain is often initially attributed to a sports injury or growth-related discomfort, which can delay imaging.

The standard diagnostic path for either form involves imaging, often beginning with an MRI for soft tissue lesions or an X-ray followed by MRI for suspected bone lesions, and then a biopsy. A biopsy is the only definitive way to confirm a sarcoma diagnosis. The College of American Pathologists and other professional bodies recommend that biopsies for suspected sarcoma be performed at, or in close consultation with, a sarcoma specialist center. The reasoning is twofold. An incorrectly placed biopsy can affect what surgery is possible later, and subtype identification under the microscope requires pathologists with sarcoma-specific expertise. With more than 70 subtypes, accurate classification at diagnosis is the first step toward appropriate care.

Once a sarcoma diagnosis is confirmed, clinical research has shaped most of what is currently considered standard care. Surgical principles, the role of radiation, and the use of systemic therapy in different subtypes have all been refined through trials conducted across small networks of specialist centers over many years.

How clinical research is advancing sarcoma care

Sarcoma care has changed substantially over the past two decades, and most of the change has been driven by clinical research conducted at sarcoma specialist centers and through cooperative research networks. Several broad research directions are now active.

One direction is precision oncology. Many sarcoma subtypes are now known to be driven by specific genetic changes, including fusion genes that link two pieces of DNA that should not normally be joined. Identifying these changes allows researchers to develop therapies aimed at the specific molecular driver of a given subtype rather than at sarcoma as a whole. Research in this area has expanded the number of subtypes for which a targeted therapeutic option exists.

A second direction is immunotherapy, the broad category of approaches that work by activating the body’s own immune system against cancer cells. Sarcoma has historically been considered less responsive to immunotherapy than some other cancers, but recent research has identified specific subtypes where immune-based approaches produce meaningful responses. One area of progress involves engineered cell therapies that recognize specific proteins on sarcoma cells, with a recent approval in synovial sarcoma marking the first cell therapy for a solid tumor of any kind. The broader landscape of immune-based cancer research continues to shift quickly across many tumor types.

A third direction is improving the care pathway itself. Research now extends beyond drug development into how patients are referred to specialist centers, how biopsies are timed, how genetic testing is integrated into diagnosis, and how patients are followed after care. These care-pathway studies are critical for a rare cancer where the difference between specialist and non-specialist care can be significant.

A fourth direction is pediatric and adolescent-focused research. Because more than half of sarcomas occur in younger patients, dedicated cooperative research groups have built clinical trial networks specifically for children, adolescents, and young adults, with attention to long-term effects of care in people who may live for many decades after diagnosis.

How clinical trials work for a rare cancer like sarcoma

Clinical trials are the research studies in which new diagnostic tools, new study drugs, new combinations, and new approaches to care are tested in people. For a rare and heterogeneous cancer group like sarcoma, trials are the main vehicle through which the field generates evidence for any given subtype.

Trials for rare cancers face structural challenges. The patient population for any single subtype is small and often geographically dispersed, so reaching the number of participants needed to detect a meaningful effect can take years. To address this, sarcoma research has shifted toward smaller, more efficient trial designs, basket trials that group subtypes by shared genetic features, and international cooperative networks that pool participants across many specialist centers.

Joining a clinical trial begins with a basic question about whether a person is a possible match. Each trial defines its own eligibility criteria, which are the medical, demographic, and disease-stage requirements a participant must meet. Eligibility for sarcoma trials usually depends on subtype, prior care received, and the location and stage of the disease. Most people who explore a sarcoma trial will find that some criteria fit and others do not, which is normal across all clinical research. How eligibility is determined is one of the most common questions among people considering participation for the first time.

DecenTrialz works in this space. The platform uses AI to match potential participants to clinical trials they may qualify for. A registered nurse then completes an initial pre-screening review before referring the candidate to the research site team. The research site handles the walk-through of the study, eligibility assessment, informed consent, and enrollment. The model is designed to give people exploring rare cancer trials a clearer first step than searching trial registries on their own.

Sarcoma and Bone Cancer Awareness Month 2026

Sarcoma and Bone Cancer Awareness Month 2026 runs from July 1 to July 31. The month is a chance for the general public to learn about a cancer group that is often missed, for patients and families to find one another and the foundations that support them, and for clinicians outside specialist centers to refresh their awareness of when to refer a suspicious lump or unexplained bone pain.

For people who have been diagnosed with a sarcoma, or who are supporting someone who has, exploring whether a clinical trial fits the situation is one option worth understanding. DecenTrialz can help with that first step, matching potential participants to research that is currently recruiting and connecting them to the research site team that handles everything that follows.